Telmisartan suppresses food intake in mice via the melanocortin pathway

Obesity Research & Clinical Practice
Kenji NomaMasamitsu Nakazato

Abstract

Telmisartan, an angiotensin type 1 receptor blocker, is widely used for the treatment of hypertension and related cardiovascular and organ damage. We here describe the effects of telmisartan on food intake and body weight using C57BL/6N mice, KKAy mice that overexpress agouti protein (a mouse model of type 2 diabetes with obesity), and mice deficient for angiotensin II-1a receptor. Telmisartan combined with a high-fat diet significantly reduced food intake and body weight gain in the three groups of mice compared with respective control animals that were fed the high-fat diet without telmisartan. Telmisartan did not induce taste aversion or affect energy expenditure. Intracerebroventricular administration of agouti-related protein, a potent antagonist of the melanocortin 3 receptor (MC3-R) and melanocortin 4 receptor (MC4-R), did not stimulate feeding in telmisartan-treated mice. Telmisartan administration enhanced the alpha-melanocyte stimulating hormone-induced suppression of food intake. This study highlights a potential role for telmisartan in hypothalamic feeding regulation, including melanocortin receptors-mediated suppression of food intake and body weight gain.:

References

May 29, 1992·Biochemical and Biophysical Research Communications·H SasamuraV J Dzau
Aug 11, 1995·The Journal of Biological Chemistry·T SugayaA Otsuka
May 1, 1995·Hypertension·M de GasparoP B Timmermans
Jul 19, 2001·The Journal of Biological Chemistry·E D Rosen, B M Spiegelman
Jun 19, 2002·Naunyn-Schmiedeberg's Archives of Pharmacology·P GohlkeJ Culman
Mar 1, 2003·Obesity Reviews : an Official Journal of the International Association for the Study of Obesity·G H GoossensM A van Baak
Apr 10, 2004·American Journal of Physiology. Heart and Circulatory Physiology·James R Sowers
Jan 29, 2005·Diabetes Care·Sachiko HonjoHiroyuki Koshiyama
Apr 20, 2005·Lancet·Robert H EckelPaul Z Zimmet
Nov 2, 2006·Endocrine Reviews·Roger D Cone
Apr 6, 2007·European Journal of Pharmacology·Jörg-Peter VoigtHeidrun Fink
Aug 2, 2007·American Journal of Therapeutics·Zafar H IsrailiManuel Velasco
Oct 2, 2009·Metabolism: Clinical and Experimental·Gregory AubertAnne Zanchi

❮ Previous
Next ❯

Citations

Sep 27, 2014·British Journal of Pharmacology·Helge Müller-FielitzWalter Raasch

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Anorexia Nervosa

Anorexia nervosa (AN) is a psychiatric condition characterized by severe weight loss and secondary problems associated with malnutrition. Here is the latest research on AN.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.